Home Cart Sign in  
Chemical Structure| 64228-81-5 Chemical Structure| 64228-81-5

Structure of Atracurium besylate
CAS No.: 64228-81-5

Chemical Structure| 64228-81-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Atracurium besylate is a non-depolarizing neuromuscular blocking agent with short duration of action.

Synonyms: BW-33A; Atracurium (besylate); Wellcome 33A74

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Atracurium besylate

CAS No. :64228-81-5
Formula : C65H82N2O18S2
M.W : 1243.48
SMILES Code : O=C(CC[N+]1(C(C2=C(CC1)C=C(C(OC)=C2)OC)CC3=CC=C(C(OC)=C3)OC)C)OCCCCCOC(CC[N+]4(C(C5=C(CC4)C=C(C(OC)=C5)OC)CC6=CC=C(C(OC)=C6)OC)C)=O.O=S(C7=CC=CC=C7)([O-])=O.O=S(C8=CC=CC=C8)([O-])=O
Synonyms :
BW-33A; Atracurium (besylate); Wellcome 33A74
MDL No. :MFCD26131271
InChI Key :XXZSQOVSEBAPGS-UHFFFAOYSA-L
Pubchem ID :47320

Safety of Atracurium besylate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
peripheral blood-derived cultured mast cells (PBCMCs) 2152 µM 3 and 20 min To evaluate Atracurium-induced mast cell activation and degranulation, results showed Atracurium activates mast cells via MRGPRX2 and induces degranulation. Front Immunol. 2021 Jul 27;12:668962
HL1 mouse cardiac cells 50 µM 24 h To evaluate the effect of Atracurium on Foxo3 and its target gene expression. Results showed that Atracurium significantly activated the expression of Foxo3 and several of its target genes. Aging Cell. 2021 Aug;20(8):e13381

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Caenorhabditis elegans Wild-type N2 and mutant strains daf-16(mu86), unc-38(e264), unc-38(x20), etc. Administration via NGM medium 5 µM, 50 µM, 500 µM Continuous treatment starting from L4 stage To evaluate the effect of Atracurium on lifespan and healthspan in C. elegans. Results showed that Atracurium significantly extended lifespan and healthspan in wild-type worms, and this effect was dependent on daf-16 and unc-38 genes. Aging Cell. 2021 Aug;20(8):e13381

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

0.80mL

0.16mL

0.08mL

4.02mL

0.80mL

0.40mL

8.04mL

1.61mL

0.80mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories